Navigation Links
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
Date:4/14/2008

- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for

BSI-201 at 2008 AACR Annual Meeting -

SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.

"We are excited to share emerging data on the therapeutic potential of BSI-201 as a novel oncology platform drug, in the area of DNA repair inhibition," said Hoyoung Huh, M.D., Ph.D., President and CEO of BiPar Sciences. "BSI-201 represents an innovative therapeutic candidate which is well positioned as both monotherapy and combination treatment in multiple solid tumor settings including ovarian cancer."

The data presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting today, evaluated BSI-201 as both a single agent and in combination with topotecan in human OVCAR-3 xenografts resistant to adriamycin, melphalan and cisplatin. Administered as monotherapy, BSI-201 demonstrated significant tumor growth delay and improved survival. In combination with topotecan, BSI-201 significantly inhibited tumor growth and increased the percentage of complete tumor regressions, compared with topotecan alone.

Based on the preclinical findings and positive Phase 1 results, BiPar is currently enrolling in a clinical trial of BSI-201 in combination with topotecan in advanced ovarian cancer and will soon launch a Phase 2 monotherapy trial in BRCA-negative ovarian cancer patients. These ovarian cancer trials represent an important expansion of BiPar's on-going Phase 2 programs in breast and brain cancer patients.

About BSI-201

BSI-201, a novel DNA repair inhibitor of PARP, is BiPar's lead product candidate. BSI-201 is a small molecule candidate with the potential of becoming a superior, new class of treatment that possesses in-vivo activity across a broad range of tumor types, both as monotherapy and in combination with standard-of-care chemotherapy regimens. In addition, Phase 1 studies of BSI-201 have demonstrated that the drug is well-tolerated with minimal adverse side effects. BSI-201 is currently in Phase 2 clinical trials in multiple solid tumor settings, including breast, ovarian, brain and uterine cancers.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on novel mechanisms of action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BiPar has successfully advanced BSI-201 from an IND to a broad Phase 2 solid tumor clinical program in less than two years.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
4. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
5. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
8. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
9. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
10. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. Stock-Callers.com assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: http://stock-callers.com/registration ...
(Date:6/23/2016)... Research and Markets has announced the addition ... New Global Agenda " report to their offering. ... Europe - the 2016 edition is a ... identifies the driving factors coming into play which will influence ... and in the future. It provides a wealth of knowledge ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Venture ... Golf Classic Tournament held on June 20th at the Woodmont Country Club at ... Luke’s Wings, an organization dedicated to helping service members that have been wounded in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
Breaking Medicine News(10 mins):